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Missense mutations in the ABCB6 transporter cause dominant
familial pseudohyperkalemia
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Familial Pseudohyperkalemia (FP) is a dominant red cell trait characterized by increased serum [K1] in
whole blood stored at or below room temperature, without additional hematological abnormalities. Func-
tional gene mapping and sequencing analysis of the candidate genes within the 2q35–q36 critical interval
identified—in 20 affected individuals among three multigenerational FP families—two novel heterozygous
missense mutations in the ABCB6 gene that cosegregated with disease phenotype. The two genomic sub-
stitutions altered two adjacent nucleotides within codon 375 of ABCB6, a porphyrin transporter that, in
erythrocyte membranes, bears the Langereis blood group antigen system. The ABCB6 R375Q mutation did
not alter the levels of mRNA or protein, or protein localization in mature erythrocytes or erythroid precursor
cells, but it is predicted to modestly alter protein structure. ABCB6 mRNA and protein levels increase dur-
ing in vitro erythroid differentiation of CD341 erythroid precursors and the erythroleukemia cell lines HEL
and K562. These data suggest that the two missense mutations in residue 375 of the ABCB6 polypeptide
found in affected individuals of families with chromosome 2-linked FP could contribute to the red cell K1
leak characteristic of this condition. Am. J. Hematol. 88:66–72, 2013. VC 2012 Wiley Periodicals, Inc.
Introduction
Familial pseudohyperkalemia (FP) is a dominant red cell
trait characterized by increased serum [K1] measured in
whole-blood specimens stored at or below room tempera-
ture. This dominantly inherited trait is not accompanied by
clinical symptoms or biological signs except for borderline
abnormalities of red cell shape [1]. FP Lille was described
in a large family of Flemish origin with morphologically nor-
mal red cells [2,3]. In this family, cation leak measured in
vitro in the presence of ouabain and bumetanide showed
normal K1 efflux at 378C, which increased greatly at 22
and 98C [3]. The subsequently reported asymptomatic
cases of FP Chiswick and FP Falkirk [4] were remarkable
for increased MCV. FP Lille was mapped to 2q35–q36 by
genome-wide search [5].
FP is considered as a subtype of the larger group of
leaky red blood cell (RBC) disorders that include Southeast
Asian ovalocytosis [6], dehydrated hereditary stomatocyto-
sis (DHSt) [7], overhydrated hereditary stomatocytosis
(OHSt) without or with neurological symptoms [8], and
cryohydrocytosis (CHC). There appears to be a continuum
between FP and DHSt that may be associated with
pseudohyperkalemia [7]. Several temperature-dependent
patterns of cation leak have been characterized in these
conditions by measurements of 86Rb influx insensitive to
ouabain and bumetanide [9]. FP stands out among the
leaky RBC disorders for its mild clinical and hematological
phenotype and its minimal changes in cell shape.
Mutations in several genes have been shown to cause
red cell cation leak disorders. These include SLC4A1 (an
ion exchange) in CHC and in atypical forms of hereditary
spherostomatocytosis [10,11], RHAG (Rh-associated gly-
coprotein) in isolated stomatin-deficient OHSt [12,13]
GLUT1 (glucose transporter 1) in echinocytosis with par-
oxysmal dyskinesia [14], stomatin-deficient cryohydrocyto-
sis [15] or in CHC [16] or pseudohyperkalemia and hemo-
lysis [17] with neurological symptoms, and PIEZO1
(mechanosensitive cation channel protein FAM38A) in
DHSt [18]. These findings suggest that distinct missense
mutations in various red cell membrane solute transporters
or channels generate cation leak pathways either through
the mutant proteins themselves or by deregulating one or
more independent cation permeabilities of the red cell
membrane.
Here, we report that in FP Lille, linked to chromosome
2q, and in two other FP families, the causal mutations
reside in the same codon (375) of the ABCB6 gene, encod-
ing the ABCB6 polypeptide reported to be a porphyrin
transporter [19]. This protein was recently identified in the
RBC membrane [20], where it displays the Langereis blood
group [21].
Materials and Methods
Cases reports. FP Lille was first diagnosed in a mother and
daughter [2,3] from a large family of Flemish descent. The carriers
were hematologically normal. Temperature-dependent 86Rb influx
showed a shallow slope pattern [5]. The responsible gene was mapped
to 2q35–q36 (very close to marker D2S1338), based on the analysis of
23 carriers (including the above-mentioned daughter as individual II.8)
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versus 11 noncarriers [5]. In 2011, the daughter’s RBC indices were
RBC 5 4.5 T/L, hemoglobin 5 13.7 g/dL, hematocrit 5 42.6%, MCV 5
96.0 fL, MCH 5 30.7 pg, and MCHC 5 32.2 g/dL. All RBC indices were
normal except for the slightly elevated MCV. Eleven carriers and seven
noncarriers from the FP Lille family were investigated in this study.
FP Falkirk was previously described in a family of Pakistani origin
[4,22]. The hematologic indices were normal, but macrocytosis was
noted after 24-hr storage on ice. 86Rb influx measurement as a function
of temperature showed a shoulder pattern [4], at variance with FP Lille.
This study investigated four carriers and one noncarrier from this family.
FP ‘‘East London’’ was first diagnosed in a Bangladeshi family [23].
Carriers showed high plasma [K1] values and anemia, and were con-
sidered nonhemolytic owing to the absence of reticulocytosis or jaun-
dice [7]. 86Rb influx measurement as a function of the temperature
showed a shoulder pattern slope [23], as in FP Falkirk. This study
investigated five carriers and six noncarriers from this family.
Patients and sequencing analysis. Blood was obtained for genetic
analysis from affected and unaffected family members, and from
healthy controls, after signed informed consent, according to the Decla-
ration of Helsinki. Blood collection was approved by local university
ethics committees.
Genomic DNA was prepared from peripheral blood with the Wizard
Genomic DNA purification kit (Promega, Milano, Italy). The search for
mutations was performed by direct sequencing, using 75-ng genomic
DNA. All exons and flanking splice junctions of the ABCB6 gene were
amplified by PCR in a 25 lL volume with Master Mix 2X. Oligonucleo-
tide primers were designed by the program Primer3 v.0.4.0. Primer
sequences are available on request. The integrity of PCR products was
checked by agarose gel electrophoresis. Direct sequencing was per-
formed using the BigDye1 Terminator Cycle Sequencing Kit (Applied
Biosystems, Branchburg, NJ) and a 3730 DNA Analyzer (Applied Bio-
systems). Missense substitution mutations in ABCB6 (Q9NP58) were
evaluated by the PolyPhen2 program [24].
Reticulocyte isolation. Reticulocytes were isolated from peripheral
blood of II.8 patient and healthy controls according to a previously
described protocol [25].
RNA isolation and cDNA synthesis from CD341 cells. Total RNA
was isolated [26] from CD341 cells at days 0, 7, and 14 of erythroid dif-
ferentiation. Single-strand cDNA was synthesized from 2 lg RNA tem-
plate, using 2.5 units VILO reverse transcriptase (Life Technologies,
Monza, Italy), and 2.5 lM oligo-dT as primer, in a total final volume of
20 lL.
Bioinformatic modeling of ABCB6 protein structure. Three-dimen-
sional (3D) structural models were generated of homodimeric human
WT ABCB6 and of the corresponding regions of the two mutant ABCB6
polypeptides R375Q and R375W. The ABCB1A/MDR1a multidrug
transporter protein of Mus musculus (RCSB PDB ID 3G5U) served as
a reference template for the inward-facing conformation of ABCB6. For
inward conformation modeling, ABCB6 amino acid sequences (Uniprot
Q9NP58) encompassing residues 237–826 and residues 246–826 were
aligned onto the structurally characterized mABCB1A sequences of
Val33-Thr626 and Leu684-Ala1271, respectively. The Sav1866 ABC
transporter of Staphylococcus aureus (RCSB PDB ID 2HYD) served as
a reference template for the outward-facing conformation of ABCB6.
Outward conformational modeling of ABCB6 aligned ABCB6 residues
248–827 onto the structurally characterized sequence of Sav1866
(Met1-Leu578).
Sequences were aligned using the program ClustalW2. The aligned
ABCB6 sequences were manually adjusted to redefine secondary
structural regions as predicted by PSIPRED. MODELLER v9.9 [27]
was used to generate 100 structural models of each of the above-
defined regions of WT ABCB6 and the two mutant proteins, in both
inward- and outward-facing conformations. The best five structural
models of each polypeptide with lowest objective function values (as
implemented in MODELLER) were subjected to energy minimization
in GROMACSv4.5.4 [28]. Structural models were converged using
steepest-descent energy minimization with 1,000 steps of step size
0.01 nm. The stereochemical quality of each energy-minimized struc-
ture was assessed by PROCHECK [28a]. The average of three mod-
els of highest stereochemical quality was chosen to represent the
ABCB6 structural model for each inward- and outward-facing confor-
mation. 3D structural models were visualized and aligned using Mol-
Mol [29] and PyMOL (Molecular Graphics System, Version 1.5.0.4
Schro¨dinger, LLC). Figures were prepared in PyMOL. Note that each
modeled dimeric ABCB6 polypeptide lacks its ‘‘M0’’ region comprising
the putative ecto-N-terminal segment and the first five N-terminal-
proximal transmembrane helices. This M0 region, for which no struc-
tural template is available, is otherwise present only in seven ABCC
proteins [30].
Results
Evaluation of FP critical region candidate genes
To find the causative gene for dominantly inherited FP
linked to 2q35–q36, we applied a functional screening
method to the genes located in the critical region mapped
by Carella [5] (D2S301–D2S163; Supporting Information
Fig. 1A). We focused on 28 genes divided into functional
categories as transporters, ion channels, and surface
receptors (Supporting Information Fig. 1B). To reduce the
number of genes to be evaluated, we filtered with gene
expression information from Unigene (NCBI http://
www.ncbi.nlm.nih.gov/unigene) and Genecard (Weizmann
Institute of Science http://www.genecards.org/). Finally, we
integrated the publicly available data with experimental
expression data on CD341 cells during erythroid differentia-
tion. We selected ABCB6 as a candidate gene based on its
elevated expression in blood and bone marrow and its
increased expression during erythroid differentiation (data
not shown). The encoded ABCB6 protein is involved in por-
phyrin transport [19] and was recently identified in the RBC
membrane [20].
ABCB6 mutational analysis
We sequenced the ABCB6 gene in 20 affected FP
patients and 14 nonaffected family members from three
affected families. Pedigrees are shown in Supporting Infor-
mation Fig. 2 for FP Lille [5], for FP Falkirk [4], and for FP
East London [23]. In FP Lille family, we analyzed 11 individ-
uals and found the heterozygous mutation c.1124 G > A,
p.R375Q (Fig. 1) in seven affected subjects. The mutation
was absent in the four healthy subjects of the same family.
In family FP Falkirk, we found the heterozygous mutation,
c.1123 C > T, p.R375W in four affected subjects (shown in
the exon–intron diagram, Fig. 1A). No mutation was found
in one unaffected subject tested in this family. The hetero-
zygous mutation in family FP East London in five affected
subjects was identical to that in FP Falkirk, c.1123 C > T,
p.R375W. No mutation was found in the six unaffected sub-
jects of this family. The two different mutations were associ-
ated with distinct temperature-dependent patterns of eryth-
rocyte cation leak. Thus, erythrocytes from affected individ-
uals with FP Lille (p.R375Q) exhibited a shallow slope
curve, whereas erythrocytes from affected individuals with
FP Falkirk and FP East London (p.R375W) exhibited a
shoulder-shaped curve. None of the carriers exhibited
abnormalities of the iris or retina. The recessive, loss-of-
function mutations associated with the Lan (2/2) blood
group were not present in FP individuals.
The two genomic mutations, encoding substitutions of
two adjacent nucleotides within the same codon, produce
different missense changes in the same amino acid residue
(Arg 375), as shown in Fig. 1A,B. Neither nucleotide
change was present in the 1,000 genomes database, or in
50 healthy subjects (unrelated to the three families ana-
lyzed). Amino acid residue R375 of ABCB6 is conserved
among all species analyzed (Fig. 1C). The two missense
mutations found in our three FP families each have
PolyPhen2 scores (http://genetics.bwh.harvard.edu/pph2/
index.shtml) of 1.000 (probably damaging).
Structural Modeling of wild-type and mutant ABCB6
To assess the potential effects of the identified mutations
on protein structure, we generated 3D structural models of
(putatively dimeric) human WT ABCB6 residues 231–827
(Fig. 2) and the corresponding regions of the two mutant
ABCB6 polypeptides R375Q and R375W (Supporting
Information Figs. 3 and 4), using as reference templates for
the inward-facing conformation the crystal structure of
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M. musculus ABCB1A/MDR1, a multidrug transporter pro-
tein (RCSB PDB ID 3G5U) [31], and for the outward-facing
conformation the crystal structure of S. aureus ABC trans-
porter Sav1866 (RCSB PDB ID 2HYD) [32]. Arg 375 is high-
lighted in blue in both inward-facing and outward-facing mod-
els. This site of FP missense mutations is situated at or close
to the cytoplasmic surface of the lipid bilayer, below the pro-
posed substrate binding site (red webbing) in the inward con-
formation form of the protein, with the guanidinium groups of
the two monomers well separated (Fig. 2A). In the modeled
outward-facing conformation, Arg 375 lies adjacent to or
within the proposed ABCB6 intermonomeric substrate bind-
ing region, with the guanidinium NH2 atoms of each mono-
mer’s R375 residue separated by 5.5 A˚ only (Figs. 2B,C).
Within the modeled dimer, the intermonomeric separations
between side-chain amide nitrogens of mutant 375Q and
between side-chain indole nitrogens of mutant 375W are
modeled as larger, between 6.5 and 7.7 A˚ (data not shown),
but the large structural differences between the modeled
inward and the outward conformations of ABCB6 are mini-
mally affected by the FP mutant missense substitutions
(Supporting Information Figs. 3 and 4). Both mutations are
predicted to produce modest changes in global protein struc-
ture as shown by the regions of slightly divergent alignment
of the WT and mutated proteins, slightly larger in the inward
than in the outward conformations (Supporting Information
Figs. 3 and 4).
ABCB6 expression in blood and red cells of affected
and unaffected subjects
ABCB6 mRNA expression in blood was indistinguishable
between affected individual II.8 and unaffected subject
III.10 from FP Lille family [4] and the four other unrelated
healthy subjects (Fig. 3A). ABCB6 protein expression in red
cells of affected individual II.8 was also equivalent to that in
healthy controls, as judged by immunoblot (Fig. 3B).
ABCB6 localization in RBCs was evaluated in patient II.8.
Confocal microscopy analysis showed that ABCB6 was
expressed at the RBC membrane, and colocalized in some
membrane regions with CD55 (Decay Accelerating Factor
bearing the Cromer blood group system) (Fig. 3C), in
agreement with the recently published results [21]. We fur-
ther confirmed ABCB6 localization in the red cell mem-
brane by substantial colocalization with glycophorin A in
control red cells (Fig. 3D) (for a negative control of ABCB6
red cell immunostaining, see Supporting Information Fig.
5A). Thus, mutant R375Q–ABCB6 is expressed at normal
levels and is localized normally in the mature red cell mem-
brane in 2q FP Lille.
ABCB6 expression during erythroid differentiation
The previous results demonstrated that ABCB6 is
expressed in RBCs and during erythroid differentiation of
K562 cells [20,21]. We examined ABCB6 expression and
localization in an ex vivo model of erythroid differentiation.
CD341 hematopoietic precursors induced to erythroid
Figure 1. Mutations analysis. A. Diagram showing ABCB6 gene sequence (blue square: exons, black bars: introns); the arrows indicate the single codon which has
undergone two missense substitutions in three families previously mapped to chromosome 2q (Left: FP Lille; Right: FP Falkirk and FP East London) Nucleotide number-
ing reflects cDNA numbering with 11 corresponding to the A of ATG translation initiation codon in the reference sequence (Ensembl transcript ID ENST00000265316).
The initiation codon is codon 1. B. Schematic representation of the two-dimensional structure of ABCB6 in the RBC membrane, based on the experimentally supported
structure of Fukuda [47]. Circles represent individual amino acid residues. The arrow indicates the ABCB6 residue mutated in the three FP families. Gray boxes depict
putative transmembrane domains (with residue numbers above and below indicating HMMTOP-predicted transmembrane domain boundaries). Amino acids of the nucleo-
tide-binding domain (NBD, blue circles) include those directly involved in ATP binding (red circles). The purple circle is the mutated amino acid in the three families stud-
ied here. Green circles are consensus N-glycosylation sites, only one of which (branched glycan symbol at residue 6) is experimentally validated by Fukuda [47]. C. Evo-
lutionary conservation of mutated residue Arg 375 (red box), across the species indicated at right (with Uniprot codes).
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differentiation with 14-day erythropoietin treatment, as
detailed in Materials and Methods section. We analyzed
ABCB6 mRNA expression during erythroid differentiation
on day 7, the stage of proerythroblast expansion and matu-
ration, and on day 14, when most cells resemble late-stage
erythroblasts. As shown in Fig. 4A, ABCB6 mRNA was
significantly upregulated after 14 days of erythropoietin
treatment (P 5 0.002 ). These data were confirmed at the
protein level by Western blotting (Fig. 4B).
We analyzed the expression of ABCB6 mRNA and pro-
tein in two additional in vitro cellular models widely used to
study hematopoietic cell growth and differentiation: HEL
cells and K562 cells. The HEL and K562 cells were differ-
entiated through the erythroid lineage with hemin for 6
days, as described in Materials and Methods section. In
HEL cells, ABCB6 mRNA levels increased after 4 days of
differentiation and remained stable at 6 days (Supporting
Information Fig. 6A). These data were confirmed at the pro-
tein level by immunoblot (Supporting Information Fig. 6B).
In K562 cells, ABCB6 mRNA levels increased gradually at
7 and 14 days (Supporting Information Fig. 6C), in parallel
with gradual increases in protein levels detected by immu-
noblot (Supporting Information Fig. 5D). Confocal micros-
copy analysis showed that ABCB6 was expressed on the
RBC membrane of CD341 cells during erythroid differentia-
tion and colocalized with the membrane marker CD55 in
some membrane regions (Fig. 4C).
Discussion
We have identified two missense mutations in residue
375 of the ABCB6 transporter that cause FP, a dominant
red cell trait characterized by an increase of serum [K1]
detectable only after ex vivo storage of whole blood at
room temperature or in the cold, in the absence of any
other hematological abnormality. The responsible gene in
FP Lille was previously mapped to 2q35–36. ABCB6 was
selected as a strong candidate gene within the critical
region based on its expression in CD341 cells during ery-
throid differentiation. Affected individuals in FP Lille exhib-
ited the c.1124 G > A, p.R375Q mutation in ABCB6.
Affected subjects in FP Falkirk and FP East London fami-
lies exhibited the ABCB6 mutation c.1123 C > T, pR375W
affecting the same codon.
ABCB6 belongs to the family of ATP-binding cassette
(ABC) transporters, one of the most abundant families of
integral membrane proteins [33]. The ABC transporters
couple ATP binding and hydrolysis to the transport of
endogenous and xenobiotic substrates across cellular
membranes. ABCB6 is a member of the B (MDR/TAP) sub-
family of ABC transporters best known as drug-resistance
genes, and it can form homodimers [19]. Indeed, increased
ABCB6 expression correlates with increased drug resist-
ance in multiple cell lines [34,35]. A specific ABCB6 func-
tion was first described in Saccharomyces cerevisiae
mutants lacking mitochondrial ABC transporter Atm1p [36].
Complementation of Atm1p-deficient yeast with human
ABCB6 rescued the phenotypic alterations, leading to the
proposal that ABCB6 is the human ortholog of Atm1p [36].
In 2006, ABCB6 was shown to catalyze mitochondrial
uptake of coproporphyrin III, as an important regulator of
cellular porphyrin biosynthesis [19]. However, Tsuchida [37]
questioned the mitochondrial localization of ABCB6, provid-
ing evidence for its localization in endoplasmic reticulum
and Golgi membranes, rather than in mitochondria. The
observation of extra-mitochondrial localization has been
extended by the study of dominantly inherited ABCB6
mutations in patients with ocular coloboma [38].
Gene expression profiling studies of zebrafish blood
formation mutants revealed ABCB6 among genes of the
erythroid cluster [39]. ABCB6 was recently shown to carry
the Lan (Langereis) blood group antigen system of the
RBC plasma membrane [21]. The asymptomatic Lan (2/2)
carriers display a variety of recessive null mutations, all
with red cells of normal phenotype [21]. Lan blood group
mismatch can cause hemolytic transfusion reactions and
hemolytic disease of the newborn. Kiss [20] recently con-
firmed ABCB6 as a glycoprotein present in the membrane
of mature erythrocytes and in exosomes released from re-
Figure 2. 3D structure models of ABCB6 in inward conformation. A. 3D structural
model of homodimeric WT human ABCB6 protein in an inward-facing conforma-
tion, as modeled on the aligned structure of M. musculus ABCB1A (PDB ID
3G5U; see Materials and Methods section). Monomer ‘‘a’’ represents ABCB6 aa
residues 246 (N-) to 826 (-C) modeled on the transmembrane helices 1–6 and
NBD1 of ABCB1A. Monomer ‘‘b’’ represents ABCB6 aa residues 237 (N0-) to 826
(-C0) modeled on ABCB1A transmembrane helices 7–12 and NBD2. A space-filling
model (light green) is superimposed on the modeled polypeptide backbone ribbon
structure (dark green). Arg375 (highlighted in blue) is located between the mem-
brane-spanning helices and the NBDs, extending into the cytoplasmic vestibule of
the dimer. The cavity (red webbing) at the intermonomeric interface outlines a
postulated intramembranous binding site for inhibitors of ABCB6-mediated porphy-
rin transport [48] corresponding to the ABCB1 binding site of inhibitor QZ59 [31].
B. Transverse intramembranous profile of the modeled inward-facing conformation
of dimeric ABCB6, with transmembrane helices rotated (around the axis shown)
908 away from the reader. The view, lacking NBDs, is from the cytoplasmic edge
of the inner leaflet, near the separated Arg375 residues (magenta), looking out-
ward. The colored M1 domain helices are numbered 6–11 for ABCB6 monomer
‘‘a,’’ and 60–110 for monomer ‘‘b’’ of the ABCB6 dimer. Helices are labeled at ends
closest to the reader. The arrows between helices 9 and 11 on one side, and heli-
ces 90 and 110 on the other side of the dimer mark the locations of side apertures
proposed in mouse ABCB1 to mediate hydrophobic drug uptake from the inner
leaflet of the lipid bilayer for subsequent efflux from the cell, or for flippase-like
transfer to the outer leaflet. C. 3D structural model of homodimeric WT human
ABCB6 protein in an outward-facing conformation, as modeled on the aligned
structure of S. aureus Sav1866 (PDB ID 2HYD). The black oval encloses a central
cavity at the intermonomeric interface, hypothesized to be an intramembranous
substrate binding site (as predicted for homodimeric Sav1866 of S. aureus) [32].
Note that each ABCB6 monomer lacks its ectofacial N-terminal tail and putative
transmembrane spans 1–5, but includes putative transmembrane spans 6–11
(TM) followed by the single-nucleotide-binding domain (NBD). D. Transverse intra-
membranous profile of the modeled outward-facing conformation of dimeric
ABCB6, with the transmembrane helices rotated (around the axis shown) 908
toward the reader. The view, lacking NBDs, is from the edge of the outer leaflet
looking inward toward the approximated Arg 375 residues (magenta) near the
cytoplasmic face of the inner leaflet. Helices are labeled at ends closest to the
reader.
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ticulocytes during the final steps of erythroid maturation.
Knockdown studies demonstrated that ABCB6 function is
not required for de novo heme biosynthesis in differentiat-
ing K562 cells, excluding this ABC transporter as an essen-
tial regulator of porphyrin synthesis. We confirm that
ABCB6 is upregulated during erythroid differentiation and is
localized at the plasma membrane in mature RBCs and in
CD341 during the erythroid differentiation (Figs. 3 and 4).
Abcb62/2 mice exhibit a grossly normal phenotype, but
lack ATP-dependent mitochondrial uptake of coproporphyrin
III. ABCB6 deficiency upregulates heme and iron pathways
that are necessary for normal development. However, in
conditions of extreme demand for porphyrins (such as dur-
ing phenylhydrazine stress), these adaptations appear inad-
equate, suggesting the importance of ABCB6 for optimal
survival under these stress conditions [40].
The FP mutation site encoding ABCB6 Arg 375 is a CpG
sequence, the usual context of human mutational hotspots,
in which C > T and G > A mutations likely result from
deamination of methylated cytosine [41]. The FP mutations
did not alter mRNA or protein abundance, as shown in the
FP Lille subject (Fig. 3). However, the mutations could
affect ABCB6 protein structure or conformational dynamics.
Arg 375 is predicted to reside at or near the junction of
cytoplasmic loop 4 and the inner leaflet portion of trans-
membrane helix 8 of ABCB6 (Figs. 1B and 2). The residue
lies within a conserved RGT sequence in which the b3
integrin cytoplasmic domain contributes to outside-in signal-
ing [42]. The corresponding residue N186 of the cystic fi-
brosis transmembrane regulator (CFTR/ABCC4) has been
modeled to contribute to a hydrophilic ring surrounding the
enlarging cytoplasmic vestibule of the CFTR anion translo-
Figure 3. Characterization of ABCB6 in patient’s RBCs. A. ABCB6 mRNA levels in peripheral blood samples of Lille patient II.8 and control subjects (pool of four sub-
jects). Values are means ± s.e.m. of three independent experiments. B. Immunoblot showing ABCB6 protein expression in RBC membrane of Lille patients II.8 and from
the four pooled control subjects. GAPDH is loading control. One of the two similar experiments. C. Laser-scanning confocal microscopy images of RBCs smear of Lille
patients II.8 and control samples analyzed by immunofluorescence with ABCB6 rabbit polyclonal antibody (red) and CD55 (membrane marker, green) showing the merge
of the two signals (Rr 5 0.44, R 5 0.79 for Lille patient II.8; Rr 5 0.15, R 5 0.48 for control sample). D. Laser-scanning confocal immunofluorescence microscopy images
of a control RBC smear costained with rabbit polyclonal antibody to ABCB6 (red) and mouse monoclonal antibody to glycophorin A (membrane marker, green) showing
the merge of the two signals (Rr 5 0.60, R 5 0.79). DIC indicating the differential interference contrast to demonstrate the presence of the RBCs. Cells were imaged
with a Zeiss LSM 510 metaconfocal microscope equipped with a 1.4 NA oil immersion plan Apochromat 1003 objective. Luminosity and contrast were adjusted using the
Axiovision software. Representative of three independent experiments.
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cation pathway [43]. The CFTR mutation N186K encoding
a likely loss-of-function variant has been found in a com-
pound heterozygous cystic fibrosis patient in trans with the
most common loss-of-function mutation DF508 (ID:3215 at
www.umd.be/CFTR) [44].
Our models of ABCB6 structure predict small distortions
by FP mutations at residue 375 in both the transmembrane
spans and the NBD. Arg 375 is modeled near a postulated
substrate-binding site and perhaps along the substrate
translocation pathway of ABCB6 in the outward-facing con-
formation. In view of the modeled intermonomeric proximity
of the two Arg 375 residues, the FP missense mutations at
this site might modify the rigid body motions proposed for
transmembrane domain cytoplasmic loops during the ATP
hydrolysis-driven transport conformational cycle [45], or
otherwise impede the transport cycle. These changes could
lead either to cation leak through the normal substrate
translocation pathway of ABCB6, or to the generation of a
novel constitutive or cyclic leak pathway through the pro-
tein. Alternatively, mutant ABCB6 polypeptides could acti-
vate an independent cation permeability through direct or
indirect protein–protein interaction, as proposed for CHC
mutations in AE1/SLC4A1 [11,15], stomatin-deficient OHSt
mutations in RhAG [12,13], and suggested by the fourfold
elevation of K–Cl cotransport observed in red cells of
patient FP Lille (LdeF, unpublished data).
ABCB6 mutations cause at least three phenotypically dis-
parate diseases: ocular coloboma, Lan (2/2) group, and FP.
The absence of the ABCB6 protein, as in individuals with the
Lan (2/2) blood group, is associated, in addition to loss of
the blood group reactivity, only with porphyrin levels that are
slightly increased in red cells and decreased in serum. This
mild phenotype, along with that of the grossly normal
Abcb62/2 mouse [40], suggests functional compensation by
other ABC transporters such as ABCG2. The absence of sig-
nificant phenotypic alteration in ABCB6 loss-of-function mod-
els demonstrates that hypomorphic and null mutations of
ABCB6 expression are of only modest pathological import
under unstressed conditions. In contrast, stable structural
abnormalities of ABCB6, as in ocular coloboma (incomplete
closure of the optic fissure) and FP, cause divergent pheno-
types. The ocular coloboma mutations likely decrease
ABCB6 function, as suggested by Wang [38]. The ABCB6
mutations of ocular coloboma preferentially affect the eyes,
perhaps reflecting the importance of ABCB6 functions in mi-
tochondria and other intracellular organelles especially im-
portant to the high-energy requirements and oxidative stress
in cells of the eye. In contrast, mature RBCs lack mitochon-
dria, following their autophagic removal in the final stages of
erythroid differentiation [38,46].
Conclusions
In conclusion, FP is very likely caused by dominant
ABCB6 mutations that appear to be gain-of-function muta-
tions causing abnormal loss of K1 from RBCs, more evi-
dent at low temperature. Ongoing functional analysis in ery-
Figure 4. ABCB6 expression and localization in CD341 during erythroid differentiation. A. ABCB6 mRNA levels (normalized to GADPH) in CD341 cells induced to erythroid
differentiation by EPO at 0, 7, and 14 days by qRT-PCR. *P-value 0.02 (CD341 14D vs. CD341 7D). B. Immunoblot of ABCB6 protein in CD341 cells induced to erythroid dif-
ferentiation at 0, 7, and 14 days using Western blots. GAPDH serves as loading control (one of the two similar experiments). C. Laser-scanning confocal immunofluorescence
microscopy images of CD341 cells induced to differentiation by EPO, showing the merge of the two signals ABCB6 (red) and CD55 (green) (Rr 5 0.66, R 5 0.89 for CD341
at day 0; Rr 5 0.35, R 5 0.40 at day 7; Rr 5 0.74, R 5 0.71 for CD341 at day 14). Cells were imaged with a Zeiss LSM 510 metaconfocal microscope equipped with a 1.4 NA
oil immersion plan Apochromat 633 objective. Luminosity and contrast were adjusted using the Axiovision software. Representative of three independent experiments.
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throid cells and in animal models should further elucidate
the pathogenic mechanisms of ABCB6 mutations in FP.
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